New England Journal of Medicine· 2012Q1

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger et al.

1,803citations
Q1SCImago
2012year

Short summary

Ruxolitinib, a JAK inhibitor, significantly reduced spleen volume by at least 35% in 28% of myelofibrosis patients within 48 weeks, compared to 0% on best available therapy (BAT).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine